nodes	percent_of_prediction	percent_of_DWPC	metapath
Rosiglitazone—PPARG—Irinotecan—Topotecan—ovarian cancer	0.0184	1	CbGdCrCtD
Rosiglitazone—ACSL4—myometrium—ovarian cancer	0.0156	0.0686	CbGeAlD
Rosiglitazone—ACSL4—uterine cervix—ovarian cancer	0.0121	0.0534	CbGeAlD
Rosiglitazone—PTGS1—oviduct—ovarian cancer	0.0117	0.0516	CbGeAlD
Rosiglitazone—ACSL4—decidua—ovarian cancer	0.0116	0.0508	CbGeAlD
Rosiglitazone—ACSL4—endometrium—ovarian cancer	0.011	0.0483	CbGeAlD
Rosiglitazone—ACSL4—gonad—ovarian cancer	0.0102	0.0448	CbGeAlD
Rosiglitazone—ACSL4—uterus—ovarian cancer	0.0101	0.0445	CbGeAlD
Rosiglitazone—ACSL4—female reproductive system—ovarian cancer	0.0091	0.04	CbGeAlD
Rosiglitazone—ACSL4—bone marrow—ovarian cancer	0.00859	0.0377	CbGeAlD
Rosiglitazone—ACSL4—female gonad—ovarian cancer	0.00828	0.0364	CbGeAlD
Rosiglitazone—ACSL4—vagina—ovarian cancer	0.00823	0.0362	CbGeAlD
Rosiglitazone—ACSL4—testis—ovarian cancer	0.00734	0.0323	CbGeAlD
Rosiglitazone—PPARG—embryo—ovarian cancer	0.00675	0.0297	CbGeAlD
Rosiglitazone—PPARG—epithelium—ovarian cancer	0.00551	0.0242	CbGeAlD
Rosiglitazone—ACSL4—lymph node—ovarian cancer	0.00532	0.0234	CbGeAlD
Rosiglitazone—PPARG—decidua—ovarian cancer	0.00521	0.0229	CbGeAlD
Rosiglitazone—SLCO1B1—female reproductive system—ovarian cancer	0.00475	0.0209	CbGeAlD
Rosiglitazone—PPARG—uterus—ovarian cancer	0.00455	0.02	CbGeAlD
Rosiglitazone—CYP2A6—vagina—ovarian cancer	0.00435	0.0191	CbGeAlD
Rosiglitazone—PPARG—female reproductive system—ovarian cancer	0.00409	0.018	CbGeAlD
Rosiglitazone—PPARG—bone marrow—ovarian cancer	0.00387	0.017	CbGeAlD
Rosiglitazone—PPARG—female gonad—ovarian cancer	0.00373	0.0164	CbGeAlD
Rosiglitazone—PPARG—vagina—ovarian cancer	0.0037	0.0163	CbGeAlD
Rosiglitazone—PPARG—testis—ovarian cancer	0.0033	0.0145	CbGeAlD
Rosiglitazone—CYP2C8—endometrium—ovarian cancer	0.00326	0.0143	CbGeAlD
Rosiglitazone—ALB—testis—ovarian cancer	0.0031	0.0136	CbGeAlD
Rosiglitazone—PTGS1—epithelium—ovarian cancer	0.00295	0.0129	CbGeAlD
Rosiglitazone—PTGS1—uterine cervix—ovarian cancer	0.00292	0.0128	CbGeAlD
Rosiglitazone—CYP2C19—vagina—ovarian cancer	0.0028	0.0123	CbGeAlD
Rosiglitazone—CYP2C8—female reproductive system—ovarian cancer	0.0027	0.0119	CbGeAlD
Rosiglitazone—PTGS1—endometrium—ovarian cancer	0.00264	0.0116	CbGeAlD
Rosiglitazone—CYP2C8—vagina—ovarian cancer	0.00244	0.0107	CbGeAlD
Rosiglitazone—PTGS1—uterus—ovarian cancer	0.00243	0.0107	CbGeAlD
Rosiglitazone—CYP2C9—female reproductive system—ovarian cancer	0.0024	0.0105	CbGeAlD
Rosiglitazone—PPARG—lymph node—ovarian cancer	0.00239	0.0105	CbGeAlD
Rosiglitazone—ALB—lymph node—ovarian cancer	0.00225	0.00987	CbGeAlD
Rosiglitazone—Thrombocytopenia—Chlorambucil—ovarian cancer	0.0022	0.00429	CcSEcCtD
Rosiglitazone—Leukopenia—Topotecan—ovarian cancer	0.00219	0.00428	CcSEcCtD
Rosiglitazone—PTGS1—female reproductive system—ovarian cancer	0.00219	0.00962	CbGeAlD
Rosiglitazone—Cardiac failure congestive—Docetaxel—ovarian cancer	0.00219	0.00427	CcSEcCtD
Rosiglitazone—CYP2C8—testis—ovarian cancer	0.00218	0.00957	CbGeAlD
Rosiglitazone—Immune system disorder—Vinorelbine—ovarian cancer	0.00217	0.00424	CcSEcCtD
Rosiglitazone—Leukopenia—Melphalan—ovarian cancer	0.00214	0.00419	CcSEcCtD
Rosiglitazone—Malnutrition—Vinorelbine—ovarian cancer	0.00209	0.00409	CcSEcCtD
Rosiglitazone—Nasopharyngitis—Paclitaxel—ovarian cancer	0.00209	0.00408	CcSEcCtD
Rosiglitazone—Arthralgia—Topotecan—ovarian cancer	0.00208	0.00407	CcSEcCtD
Rosiglitazone—Myalgia—Topotecan—ovarian cancer	0.00208	0.00407	CcSEcCtD
Rosiglitazone—Myalgia—Melphalan—ovarian cancer	0.00204	0.00398	CcSEcCtD
Rosiglitazone—Cardiac failure—Docetaxel—ovarian cancer	0.00203	0.00396	CcSEcCtD
Rosiglitazone—Hyperbilirubinaemia—Epirubicin—ovarian cancer	0.00202	0.00395	CcSEcCtD
Rosiglitazone—Back pain—Vinorelbine—ovarian cancer	0.00202	0.00395	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Topotecan—ovarian cancer	0.002	0.0039	CcSEcCtD
Rosiglitazone—PTGS1—female gonad—ovarian cancer	0.00199	0.00875	CbGeAlD
Rosiglitazone—Infection—Topotecan—ovarian cancer	0.00198	0.00387	CcSEcCtD
Rosiglitazone—PTGS1—vagina—ovarian cancer	0.00198	0.0087	CbGeAlD
Rosiglitazone—Nervous system disorder—Topotecan—ovarian cancer	0.00196	0.00382	CcSEcCtD
Rosiglitazone—Oedema—Melphalan—ovarian cancer	0.00196	0.00382	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Melphalan—ovarian cancer	0.00196	0.00382	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Topotecan—ovarian cancer	0.00196	0.00382	CcSEcCtD
Rosiglitazone—Infection—Melphalan—ovarian cancer	0.00194	0.00379	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00194	0.00378	CcSEcCtD
Rosiglitazone—Anaemia—Vinorelbine—ovarian cancer	0.00193	0.00378	CcSEcCtD
Rosiglitazone—Fatigue—Chlorambucil—ovarian cancer	0.00193	0.00378	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Melphalan—ovarian cancer	0.00191	0.00374	CcSEcCtD
Rosiglitazone—Angioedema—Vinorelbine—ovarian cancer	0.00191	0.00373	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Paclitaxel—ovarian cancer	0.00188	0.00367	CcSEcCtD
Rosiglitazone—Leukopenia—Vinorelbine—ovarian cancer	0.00187	0.00366	CcSEcCtD
Rosiglitazone—Hyperbilirubinaemia—Doxorubicin—ovarian cancer	0.00187	0.00366	CcSEcCtD
Rosiglitazone—Weight increased—Paclitaxel—ovarian cancer	0.00184	0.00359	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Paclitaxel—ovarian cancer	0.00182	0.00356	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.00182	0.00355	CcSEcCtD
Rosiglitazone—Hypertension—Vinorelbine—ovarian cancer	0.00181	0.00353	CcSEcCtD
Rosiglitazone—CYP2D6—female reproductive system—ovarian cancer	0.0018	0.0079	CbGeAlD
Rosiglitazone—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.00179	0.00349	CcSEcCtD
Rosiglitazone—Urticaria—Chlorambucil—ovarian cancer	0.00178	0.00348	CcSEcCtD
Rosiglitazone—Arthralgia—Vinorelbine—ovarian cancer	0.00178	0.00348	CcSEcCtD
Rosiglitazone—Myalgia—Vinorelbine—ovarian cancer	0.00178	0.00348	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.00178	0.00348	CcSEcCtD
Rosiglitazone—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.00178	0.00347	CcSEcCtD
Rosiglitazone—Nasopharyngitis—Docetaxel—ovarian cancer	0.00177	0.00346	CcSEcCtD
Rosiglitazone—PTGS1—testis—ovarian cancer	0.00177	0.00776	CbGeAlD
Rosiglitazone—Myocardial infarction—Paclitaxel—ovarian cancer	0.00177	0.00345	CcSEcCtD
Rosiglitazone—Fluid retention—Epirubicin—ovarian cancer	0.00175	0.00341	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00172	0.00337	CcSEcCtD
Rosiglitazone—Fatigue—Topotecan—ovarian cancer	0.00172	0.00336	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00171	0.00334	CcSEcCtD
Rosiglitazone—Constipation—Topotecan—ovarian cancer	0.00171	0.00333	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.0017	0.00333	CcSEcCtD
Rosiglitazone—Infection—Vinorelbine—ovarian cancer	0.0017	0.00331	CcSEcCtD
Rosiglitazone—Sinusitis—Paclitaxel—ovarian cancer	0.00169	0.0033	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00169	0.0033	CcSEcCtD
Rosiglitazone—Fatigue—Melphalan—ovarian cancer	0.00169	0.00329	CcSEcCtD
Rosiglitazone—Nervous system disorder—Vinorelbine—ovarian cancer	0.00168	0.00327	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00167	0.00327	CcSEcCtD
Rosiglitazone—Pulmonary oedema—Epirubicin—ovarian cancer	0.00164	0.0032	CcSEcCtD
Rosiglitazone—CYP2D6—female gonad—ovarian cancer	0.00164	0.00719	CbGeAlD
Rosiglitazone—Fluid retention—Doxorubicin—ovarian cancer	0.00162	0.00316	CcSEcCtD
Rosiglitazone—Asthenia—Chlorambucil—ovarian cancer	0.00161	0.00314	CcSEcCtD
Rosiglitazone—Oedema peripheral—Paclitaxel—ovarian cancer	0.00159	0.00311	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Paclitaxel—ovarian cancer	0.00159	0.0031	CcSEcCtD
Rosiglitazone—Pruritus—Chlorambucil—ovarian cancer	0.00159	0.0031	CcSEcCtD
Rosiglitazone—Urticaria—Topotecan—ovarian cancer	0.00159	0.0031	CcSEcCtD
Rosiglitazone—Weight increased—Docetaxel—ovarian cancer	0.00156	0.00304	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00156	0.00304	CcSEcCtD
Rosiglitazone—Urticaria—Melphalan—ovarian cancer	0.00155	0.00303	CcSEcCtD
Rosiglitazone—Diabetes mellitus—Epirubicin—ovarian cancer	0.00154	0.003	CcSEcCtD
Rosiglitazone—Diarrhoea—Chlorambucil—ovarian cancer	0.00153	0.003	CcSEcCtD
Rosiglitazone—Hepatic function abnormal—Epirubicin—ovarian cancer	0.00153	0.00299	CcSEcCtD
Rosiglitazone—Erythema multiforme—Paclitaxel—ovarian cancer	0.00153	0.00299	CcSEcCtD
Rosiglitazone—Pulmonary oedema—Doxorubicin—ovarian cancer	0.00152	0.00296	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.00151	0.00296	CcSEcCtD
Rosiglitazone—Eye disorder—Paclitaxel—ovarian cancer	0.00151	0.00295	CcSEcCtD
Rosiglitazone—Acute coronary syndrome—Docetaxel—ovarian cancer	0.00151	0.00294	CcSEcCtD
Rosiglitazone—Cardiac disorder—Paclitaxel—ovarian cancer	0.0015	0.00293	CcSEcCtD
Rosiglitazone—Myocardial infarction—Docetaxel—ovarian cancer	0.0015	0.00292	CcSEcCtD
Rosiglitazone—Hepatic failure—Epirubicin—ovarian cancer	0.00149	0.0029	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00147	0.00288	CcSEcCtD
Rosiglitazone—Cardiac failure congestive—Epirubicin—ovarian cancer	0.00147	0.00288	CcSEcCtD
Rosiglitazone—Fatigue—Vinorelbine—ovarian cancer	0.00147	0.00288	CcSEcCtD
Rosiglitazone—Constipation—Vinorelbine—ovarian cancer	0.00146	0.00285	CcSEcCtD
Rosiglitazone—Immune system disorder—Paclitaxel—ovarian cancer	0.00146	0.00285	CcSEcCtD
Rosiglitazone—CYP2D6—testis—ovarian cancer	0.00145	0.00638	CbGeAlD
Rosiglitazone—Hepatobiliary disease—Docetaxel—ovarian cancer	0.00144	0.00282	CcSEcCtD
Rosiglitazone—Asthenia—Topotecan—ovarian cancer	0.00143	0.0028	CcSEcCtD
Rosiglitazone—Increased appetite—Epirubicin—ovarian cancer	0.00142	0.00278	CcSEcCtD
Rosiglitazone—Diabetes mellitus—Doxorubicin—ovarian cancer	0.00142	0.00278	CcSEcCtD
Rosiglitazone—Hepatic function abnormal—Doxorubicin—ovarian cancer	0.00142	0.00276	CcSEcCtD
Rosiglitazone—Pruritus—Topotecan—ovarian cancer	0.00141	0.00276	CcSEcCtD
Rosiglitazone—Malnutrition—Paclitaxel—ovarian cancer	0.00141	0.00275	CcSEcCtD
Rosiglitazone—Asthenia—Melphalan—ovarian cancer	0.0014	0.00274	CcSEcCtD
Rosiglitazone—Pruritus—Melphalan—ovarian cancer	0.00138	0.0027	CcSEcCtD
Rosiglitazone—Hepatic failure—Doxorubicin—ovarian cancer	0.00138	0.00269	CcSEcCtD
Rosiglitazone—Hepatitis—Docetaxel—ovarian cancer	0.00137	0.00268	CcSEcCtD
Rosiglitazone—Cardiac failure—Epirubicin—ovarian cancer	0.00137	0.00267	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Epirubicin—ovarian cancer	0.00137	0.00267	CcSEcCtD
Rosiglitazone—Diarrhoea—Topotecan—ovarian cancer	0.00137	0.00267	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Epirubicin—ovarian cancer	0.00136	0.00266	CcSEcCtD
Rosiglitazone—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.00136	0.00266	CcSEcCtD
Rosiglitazone—Back pain—Paclitaxel—ovarian cancer	0.00136	0.00266	CcSEcCtD
Rosiglitazone—Urticaria—Vinorelbine—ovarian cancer	0.00136	0.00265	CcSEcCtD
Rosiglitazone—Oedema peripheral—Docetaxel—ovarian cancer	0.00135	0.00264	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Docetaxel—ovarian cancer	0.00135	0.00263	CcSEcCtD
Rosiglitazone—Diarrhoea—Melphalan—ovarian cancer	0.00134	0.00261	CcSEcCtD
Rosiglitazone—Nausea—Chlorambucil—ovarian cancer	0.00133	0.0026	CcSEcCtD
Rosiglitazone—Dizziness—Topotecan—ovarian cancer	0.00132	0.00258	CcSEcCtD
Rosiglitazone—Increased appetite—Doxorubicin—ovarian cancer	0.00132	0.00257	CcSEcCtD
Rosiglitazone—Anaemia—Paclitaxel—ovarian cancer	0.0013	0.00254	CcSEcCtD
Rosiglitazone—Erythema multiforme—Docetaxel—ovarian cancer	0.0013	0.00253	CcSEcCtD
Rosiglitazone—Angioedema—Paclitaxel—ovarian cancer	0.00129	0.00251	CcSEcCtD
Rosiglitazone—Eye disorder—Docetaxel—ovarian cancer	0.00128	0.0025	CcSEcCtD
Rosiglitazone—PTGS1—lymph node—ovarian cancer	0.00128	0.00563	CbGeAlD
Rosiglitazone—Cardiac disorder—Docetaxel—ovarian cancer	0.00127	0.00248	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Doxorubicin—ovarian cancer	0.00127	0.00247	CcSEcCtD
Rosiglitazone—Cardiac failure—Doxorubicin—ovarian cancer	0.00127	0.00247	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.00126	0.00246	CcSEcCtD
Rosiglitazone—Leukopenia—Paclitaxel—ovarian cancer	0.00126	0.00246	CcSEcCtD
Rosiglitazone—Rash—Topotecan—ovarian cancer	0.00126	0.00246	CcSEcCtD
Rosiglitazone—Dermatitis—Topotecan—ovarian cancer	0.00126	0.00246	CcSEcCtD
Rosiglitazone—Headache—Topotecan—ovarian cancer	0.00125	0.00244	CcSEcCtD
Rosiglitazone—Immune system disorder—Docetaxel—ovarian cancer	0.00124	0.00242	CcSEcCtD
Rosiglitazone—Rash—Melphalan—ovarian cancer	0.00123	0.00241	CcSEcCtD
Rosiglitazone—Dermatitis—Melphalan—ovarian cancer	0.00123	0.00241	CcSEcCtD
Rosiglitazone—Asthenia—Vinorelbine—ovarian cancer	0.00123	0.00239	CcSEcCtD
Rosiglitazone—Hypertension—Paclitaxel—ovarian cancer	0.00122	0.00237	CcSEcCtD
Rosiglitazone—Pruritus—Vinorelbine—ovarian cancer	0.00121	0.00236	CcSEcCtD
Rosiglitazone—Arthralgia—Paclitaxel—ovarian cancer	0.0012	0.00234	CcSEcCtD
Rosiglitazone—Myalgia—Paclitaxel—ovarian cancer	0.0012	0.00234	CcSEcCtD
Rosiglitazone—Nasopharyngitis—Epirubicin—ovarian cancer	0.0012	0.00233	CcSEcCtD
Rosiglitazone—Malnutrition—Docetaxel—ovarian cancer	0.00119	0.00233	CcSEcCtD
Rosiglitazone—Nausea—Topotecan—ovarian cancer	0.00119	0.00232	CcSEcCtD
Rosiglitazone—Diarrhoea—Vinorelbine—ovarian cancer	0.00117	0.00228	CcSEcCtD
Rosiglitazone—Nausea—Melphalan—ovarian cancer	0.00116	0.00227	CcSEcCtD
Rosiglitazone—Back pain—Docetaxel—ovarian cancer	0.00115	0.00225	CcSEcCtD
Rosiglitazone—Oedema—Paclitaxel—ovarian cancer	0.00115	0.00224	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00115	0.00224	CcSEcCtD
Rosiglitazone—Infection—Paclitaxel—ovarian cancer	0.00114	0.00223	CcSEcCtD
Rosiglitazone—Dizziness—Vinorelbine—ovarian cancer	0.00113	0.00221	CcSEcCtD
Rosiglitazone—Nervous system disorder—Paclitaxel—ovarian cancer	0.00113	0.0022	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00113	0.0022	CcSEcCtD
Rosiglitazone—Nasopharyngitis—Doxorubicin—ovarian cancer	0.00111	0.00216	CcSEcCtD
Rosiglitazone—Anaemia—Docetaxel—ovarian cancer	0.0011	0.00215	CcSEcCtD
Rosiglitazone—Rash—Vinorelbine—ovarian cancer	0.00108	0.0021	CcSEcCtD
Rosiglitazone—Dermatitis—Vinorelbine—ovarian cancer	0.00108	0.0021	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.00107	0.0021	CcSEcCtD
Rosiglitazone—Headache—Vinorelbine—ovarian cancer	0.00107	0.00209	CcSEcCtD
Rosiglitazone—Leukopenia—Docetaxel—ovarian cancer	0.00107	0.00209	CcSEcCtD
Rosiglitazone—Weight increased—Epirubicin—ovarian cancer	0.00105	0.00205	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00105	0.00204	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Epirubicin—ovarian cancer	0.00104	0.00203	CcSEcCtD
Rosiglitazone—Hypertension—Docetaxel—ovarian cancer	0.00103	0.00201	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.00102	0.00199	CcSEcCtD
Rosiglitazone—Arthralgia—Docetaxel—ovarian cancer	0.00102	0.00198	CcSEcCtD
Rosiglitazone—Myalgia—Docetaxel—ovarian cancer	0.00102	0.00198	CcSEcCtD
Rosiglitazone—Nausea—Vinorelbine—ovarian cancer	0.00101	0.00198	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000993	0.00194	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000992	0.00194	CcSEcCtD
Rosiglitazone—Fatigue—Paclitaxel—ovarian cancer	0.000991	0.00193	CcSEcCtD
Rosiglitazone—Constipation—Paclitaxel—ovarian cancer	0.000983	0.00192	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000974	0.0019	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Docetaxel—ovarian cancer	0.000974	0.0019	CcSEcCtD
Rosiglitazone—Oedema—Docetaxel—ovarian cancer	0.000974	0.0019	CcSEcCtD
Rosiglitazone—Weight increased—Doxorubicin—ovarian cancer	0.000973	0.0019	CcSEcCtD
Rosiglitazone—Infection—Docetaxel—ovarian cancer	0.000968	0.00189	CcSEcCtD
Rosiglitazone—Sinusitis—Epirubicin—ovarian cancer	0.000966	0.00189	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000964	0.00188	CcSEcCtD
Rosiglitazone—Nervous system disorder—Docetaxel—ovarian cancer	0.000955	0.00186	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Docetaxel—ovarian cancer	0.000954	0.00186	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000945	0.00184	CcSEcCtD
Rosiglitazone—Hepatitis—Epirubicin—ovarian cancer	0.000925	0.00181	CcSEcCtD
Rosiglitazone—Urticaria—Paclitaxel—ovarian cancer	0.000913	0.00178	CcSEcCtD
Rosiglitazone—Oedema peripheral—Epirubicin—ovarian cancer	0.000911	0.00178	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Epirubicin—ovarian cancer	0.000909	0.00177	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000901	0.00176	CcSEcCtD
Rosiglitazone—Sinusitis—Doxorubicin—ovarian cancer	0.000894	0.00175	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000887	0.00173	CcSEcCtD
Rosiglitazone—Erythema multiforme—Epirubicin—ovarian cancer	0.000874	0.00171	CcSEcCtD
Rosiglitazone—Eye disorder—Epirubicin—ovarian cancer	0.000864	0.00169	CcSEcCtD
Rosiglitazone—Cardiac disorder—Epirubicin—ovarian cancer	0.000858	0.00168	CcSEcCtD
Rosiglitazone—Hepatitis—Doxorubicin—ovarian cancer	0.000856	0.00167	CcSEcCtD
Rosiglitazone—Oedema peripheral—Doxorubicin—ovarian cancer	0.000843	0.00165	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000841	0.00164	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000841	0.00164	CcSEcCtD
Rosiglitazone—Fatigue—Docetaxel—ovarian cancer	0.00084	0.00164	CcSEcCtD
Rosiglitazone—Immune system disorder—Epirubicin—ovarian cancer	0.000835	0.00163	CcSEcCtD
Rosiglitazone—Constipation—Docetaxel—ovarian cancer	0.000833	0.00163	CcSEcCtD
Rosiglitazone—Asthenia—Paclitaxel—ovarian cancer	0.000824	0.00161	CcSEcCtD
Rosiglitazone—Pruritus—Paclitaxel—ovarian cancer	0.000813	0.00159	CcSEcCtD
Rosiglitazone—Erythema multiforme—Doxorubicin—ovarian cancer	0.000809	0.00158	CcSEcCtD
Rosiglitazone—Malnutrition—Epirubicin—ovarian cancer	0.000805	0.00157	CcSEcCtD
Rosiglitazone—Eye disorder—Doxorubicin—ovarian cancer	0.0008	0.00156	CcSEcCtD
Rosiglitazone—Cardiac disorder—Doxorubicin—ovarian cancer	0.000794	0.00155	CcSEcCtD
Rosiglitazone—Diarrhoea—Paclitaxel—ovarian cancer	0.000786	0.00154	CcSEcCtD
Rosiglitazone—Back pain—Epirubicin—ovarian cancer	0.000779	0.00152	CcSEcCtD
Rosiglitazone—Immune system disorder—Doxorubicin—ovarian cancer	0.000773	0.00151	CcSEcCtD
Rosiglitazone—Dizziness—Paclitaxel—ovarian cancer	0.00076	0.00148	CcSEcCtD
Rosiglitazone—Malnutrition—Doxorubicin—ovarian cancer	0.000745	0.00145	CcSEcCtD
Rosiglitazone—Anaemia—Epirubicin—ovarian cancer	0.000744	0.00145	CcSEcCtD
Rosiglitazone—Rash—Paclitaxel—ovarian cancer	0.000724	0.00141	CcSEcCtD
Rosiglitazone—Dermatitis—Paclitaxel—ovarian cancer	0.000724	0.00141	CcSEcCtD
Rosiglitazone—Leukopenia—Epirubicin—ovarian cancer	0.00072	0.00141	CcSEcCtD
Rosiglitazone—Back pain—Doxorubicin—ovarian cancer	0.00072	0.00141	CcSEcCtD
Rosiglitazone—Headache—Paclitaxel—ovarian cancer	0.00072	0.00141	CcSEcCtD
Rosiglitazone—Asthenia—Docetaxel—ovarian cancer	0.000699	0.00136	CcSEcCtD
Rosiglitazone—Hypertension—Epirubicin—ovarian cancer	0.000695	0.00136	CcSEcCtD
Rosiglitazone—Pruritus—Docetaxel—ovarian cancer	0.000689	0.00135	CcSEcCtD
Rosiglitazone—Anaemia—Doxorubicin—ovarian cancer	0.000688	0.00134	CcSEcCtD
Rosiglitazone—Arthralgia—Epirubicin—ovarian cancer	0.000685	0.00134	CcSEcCtD
Rosiglitazone—Myalgia—Epirubicin—ovarian cancer	0.000685	0.00134	CcSEcCtD
Rosiglitazone—Nausea—Paclitaxel—ovarian cancer	0.000683	0.00133	CcSEcCtD
Rosiglitazone—Leukopenia—Doxorubicin—ovarian cancer	0.000667	0.0013	CcSEcCtD
Rosiglitazone—Diarrhoea—Docetaxel—ovarian cancer	0.000666	0.0013	CcSEcCtD
Rosiglitazone—Oedema—Epirubicin—ovarian cancer	0.000657	0.00128	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000657	0.00128	CcSEcCtD
Rosiglitazone—Infection—Epirubicin—ovarian cancer	0.000653	0.00127	CcSEcCtD
Rosiglitazone—Nervous system disorder—Epirubicin—ovarian cancer	0.000644	0.00126	CcSEcCtD
Rosiglitazone—Dizziness—Docetaxel—ovarian cancer	0.000644	0.00126	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Epirubicin—ovarian cancer	0.000643	0.00126	CcSEcCtD
Rosiglitazone—Hypertension—Doxorubicin—ovarian cancer	0.000643	0.00126	CcSEcCtD
Rosiglitazone—Arthralgia—Doxorubicin—ovarian cancer	0.000634	0.00124	CcSEcCtD
Rosiglitazone—Myalgia—Doxorubicin—ovarian cancer	0.000634	0.00124	CcSEcCtD
Rosiglitazone—Rash—Docetaxel—ovarian cancer	0.000614	0.0012	CcSEcCtD
Rosiglitazone—Dermatitis—Docetaxel—ovarian cancer	0.000614	0.0012	CcSEcCtD
Rosiglitazone—Headache—Docetaxel—ovarian cancer	0.00061	0.00119	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000608	0.00119	CcSEcCtD
Rosiglitazone—Oedema—Doxorubicin—ovarian cancer	0.000608	0.00119	CcSEcCtD
Rosiglitazone—Infection—Doxorubicin—ovarian cancer	0.000604	0.00118	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000598	0.00117	CcSEcCtD
Rosiglitazone—Nervous system disorder—Doxorubicin—ovarian cancer	0.000596	0.00116	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000595	0.00116	CcSEcCtD
Rosiglitazone—Nausea—Docetaxel—ovarian cancer	0.000578	0.00113	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000567	0.00111	CcSEcCtD
Rosiglitazone—Fatigue—Epirubicin—ovarian cancer	0.000566	0.00111	CcSEcCtD
Rosiglitazone—Constipation—Epirubicin—ovarian cancer	0.000562	0.0011	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000554	0.00108	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000525	0.00102	CcSEcCtD
Rosiglitazone—Fatigue—Doxorubicin—ovarian cancer	0.000524	0.00102	CcSEcCtD
Rosiglitazone—Urticaria—Epirubicin—ovarian cancer	0.000522	0.00102	CcSEcCtD
Rosiglitazone—Constipation—Doxorubicin—ovarian cancer	0.00052	0.00101	CcSEcCtD
Rosiglitazone—Urticaria—Doxorubicin—ovarian cancer	0.000483	0.000943	CcSEcCtD
Rosiglitazone—Asthenia—Epirubicin—ovarian cancer	0.000471	0.00092	CcSEcCtD
Rosiglitazone—Pruritus—Epirubicin—ovarian cancer	0.000465	0.000907	CcSEcCtD
Rosiglitazone—Diarrhoea—Epirubicin—ovarian cancer	0.000449	0.000878	CcSEcCtD
Rosiglitazone—Asthenia—Doxorubicin—ovarian cancer	0.000436	0.000851	CcSEcCtD
Rosiglitazone—Dizziness—Epirubicin—ovarian cancer	0.000434	0.000848	CcSEcCtD
Rosiglitazone—Pruritus—Doxorubicin—ovarian cancer	0.00043	0.00084	CcSEcCtD
Rosiglitazone—Diarrhoea—Doxorubicin—ovarian cancer	0.000416	0.000812	CcSEcCtD
Rosiglitazone—Rash—Epirubicin—ovarian cancer	0.000414	0.000809	CcSEcCtD
Rosiglitazone—Dermatitis—Epirubicin—ovarian cancer	0.000414	0.000808	CcSEcCtD
Rosiglitazone—Headache—Epirubicin—ovarian cancer	0.000412	0.000804	CcSEcCtD
Rosiglitazone—Dizziness—Doxorubicin—ovarian cancer	0.000402	0.000785	CcSEcCtD
Rosiglitazone—Nausea—Epirubicin—ovarian cancer	0.00039	0.000762	CcSEcCtD
Rosiglitazone—Rash—Doxorubicin—ovarian cancer	0.000383	0.000748	CcSEcCtD
Rosiglitazone—Dermatitis—Doxorubicin—ovarian cancer	0.000383	0.000748	CcSEcCtD
Rosiglitazone—Headache—Doxorubicin—ovarian cancer	0.000381	0.000743	CcSEcCtD
Rosiglitazone—Nausea—Doxorubicin—ovarian cancer	0.000361	0.000705	CcSEcCtD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000104	0.000428	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—MMP9—ovarian cancer	0.000103	0.000428	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—SOD1—ovarian cancer	0.000103	0.000426	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—PPP2R1A—ovarian cancer	0.000102	0.000423	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	0.000102	0.000421	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	9.9e-05	0.000409	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—YAP1—ovarian cancer	9.82e-05	0.000406	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	9.72e-05	0.000402	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CYTB—ovarian cancer	9.66e-05	0.000399	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.6e-05	0.000397	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—BRIP1—ovarian cancer	9.46e-05	0.000391	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PPP1CC—ovarian cancer	9.46e-05	0.000391	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	9.45e-05	0.000391	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	9.44e-05	0.00039	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—PIK3CA—ovarian cancer	9.4e-05	0.000389	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—BRIP1—ovarian cancer	9.4e-05	0.000389	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PPP1CC—ovarian cancer	9.4e-05	0.000389	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—IL2—ovarian cancer	9.36e-05	0.000387	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—VEGFA—ovarian cancer	9.29e-05	0.000384	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—YAP1—ovarian cancer	9.28e-05	0.000384	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PPP2R1A—ovarian cancer	9.23e-05	0.000382	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—STAT3—ovarian cancer	9.2e-05	0.00038	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.18e-05	0.00038	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—NRAS—ovarian cancer	9.17e-05	0.000379	CbGpPWpGaD
Rosiglitazone—PPARG—Generic Transcription Pathway—MYC—ovarian cancer	9.08e-05	0.000375	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—FASN—ovarian cancer	9e-05	0.000372	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYTB—ovarian cancer	8.88e-05	0.000367	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—SLC5A5—ovarian cancer	8.85e-05	0.000366	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYTB—ovarian cancer	8.8e-05	0.000364	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—MAPK3—ovarian cancer	8.79e-05	0.000363	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	8.6e-05	0.000356	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—ABCB1—ovarian cancer	8.57e-05	0.000354	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—SLC2A1—ovarian cancer	8.55e-05	0.000353	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	8.54e-05	0.000353	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PPP1CC—ovarian cancer	8.44e-05	0.000349	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—BRIP1—ovarian cancer	8.44e-05	0.000349	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—TYMS—ovarian cancer	8.42e-05	0.000348	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—ESR1—ovarian cancer	8.4e-05	0.000347	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.37e-05	0.000346	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—MAPK1—ovarian cancer	8.36e-05	0.000346	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—EGFR—ovarian cancer	8.36e-05	0.000346	CbGpPWpGaD
Rosiglitazone—ALB—Transmembrane transport of small molecules—ABCB1—ovarian cancer	8.23e-05	0.00034	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—CYP1B1—ovarian cancer	8.19e-05	0.000339	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	8.07e-05	0.000334	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—FASN—ovarian cancer	8e-05	0.000331	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	7.95e-05	0.000329	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—KRAS—ovarian cancer	7.9e-05	0.000326	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—SLC5A5—ovarian cancer	7.87e-05	0.000326	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—BRIP1—ovarian cancer	7.76e-05	0.000321	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PPP1CC—ovarian cancer	7.76e-05	0.000321	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PPP1CC—ovarian cancer	7.7e-05	0.000318	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—BRIP1—ovarian cancer	7.7e-05	0.000318	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—AKT1—ovarian cancer	7.68e-05	0.000318	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—SLC2A1—ovarian cancer	7.6e-05	0.000314	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—FASN—ovarian cancer	7.57e-05	0.000313	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—CAV1—ovarian cancer	7.53e-05	0.000311	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYTB—ovarian cancer	7.52e-05	0.000311	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	7.52e-05	0.000311	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	7.45e-05	0.000308	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—SLC5A5—ovarian cancer	7.44e-05	0.000308	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	7.35e-05	0.000304	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—CYP1B1—ovarian cancer	7.29e-05	0.000301	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PPP2R1A—ovarian cancer	7.27e-05	0.0003	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.23e-05	0.000299	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—SLC2A1—ovarian cancer	7.19e-05	0.000297	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	7.16e-05	0.000296	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—CYP1B1—ovarian cancer	6.89e-05	0.000285	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.89e-05	0.000285	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—PIK3CG—ovarian cancer	6.85e-05	0.000283	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.85e-05	0.000283	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—CAV1—ovarian cancer	6.78e-05	0.00028	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—ABCB1—ovarian cancer	6.75e-05	0.000279	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—HRAS—ovarian cancer	6.71e-05	0.000278	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—TYMS—ovarian cancer	6.63e-05	0.000274	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PPP1CC—ovarian cancer	6.58e-05	0.000272	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—BRIP1—ovarian cancer	6.58e-05	0.000272	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.48e-05	0.000268	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PPP2R1A—ovarian cancer	6.47e-05	0.000267	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.43e-05	0.000266	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—IL6—ovarian cancer	6.42e-05	0.000266	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—YAP1—ovarian cancer	6.34e-05	0.000262	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—YAP1—ovarian cancer	6.31e-05	0.000261	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.28e-05	0.00026	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.24e-05	0.000258	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	6.21e-05	0.000257	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PIK3CG—ovarian cancer	6.18e-05	0.000255	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.15e-05	0.000254	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PPP2R1A—ovarian cancer	6.11e-05	0.000253	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—PIK3CD—ovarian cancer	6.03e-05	0.000249	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—ABCB1—ovarian cancer	6e-05	0.000248	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—AKT1—ovarian cancer	5.93e-05	0.000245	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—TYMS—ovarian cancer	5.9e-05	0.000244	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—ABCB1—ovarian cancer	5.68e-05	0.000235	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—YAP1—ovarian cancer	5.66e-05	0.000234	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	5.61e-05	0.000232	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.6e-05	0.000232	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—TYMS—ovarian cancer	5.58e-05	0.000231	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.52e-05	0.000228	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.49e-05	0.000227	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PIK3CD—ovarian cancer	5.43e-05	0.000225	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—CAV1—ovarian cancer	5.34e-05	0.000221	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—PIK3CB—ovarian cancer	5.25e-05	0.000217	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—YAP1—ovarian cancer	5.21e-05	0.000215	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—FASN—ovarian cancer	5.17e-05	0.000214	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—YAP1—ovarian cancer	5.16e-05	0.000213	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—FASN—ovarian cancer	5.14e-05	0.000213	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.11e-05	0.000211	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.1e-05	0.000211	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—SLC5A5—ovarian cancer	5.09e-05	0.00021	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	5.07e-05	0.00021	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—SLC5A5—ovarian cancer	5.06e-05	0.000209	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.92e-05	0.000204	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—SLC2A1—ovarian cancer	4.91e-05	0.000203	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—SLC2A1—ovarian cancer	4.88e-05	0.000202	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PIK3CG—ovarian cancer	4.86e-05	0.000201	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—IL2—ovarian cancer	4.82e-05	0.000199	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.81e-05	0.000199	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.79e-05	0.000198	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.78e-05	0.000198	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—CAV1—ovarian cancer	4.75e-05	0.000196	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PIK3CB—ovarian cancer	4.73e-05	0.000196	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CYP1B1—ovarian cancer	4.71e-05	0.000195	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CYP1B1—ovarian cancer	4.68e-05	0.000194	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—FASN—ovarian cancer	4.61e-05	0.000191	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—SLC5A5—ovarian cancer	4.54e-05	0.000188	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.54e-05	0.000188	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—MAPK3—ovarian cancer	4.49e-05	0.000186	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—CAV1—ovarian cancer	4.49e-05	0.000186	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.49e-05	0.000186	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—YAP1—ovarian cancer	4.41e-05	0.000182	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—SLC2A1—ovarian cancer	4.38e-05	0.000181	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—MYC—ovarian cancer	4.37e-05	0.000181	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.36e-05	0.00018	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PIK3CG—ovarian cancer	4.33e-05	0.000179	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.29e-05	0.000177	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PIK3CD—ovarian cancer	4.28e-05	0.000177	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—FASN—ovarian cancer	4.24e-05	0.000175	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—FASN—ovarian cancer	4.21e-05	0.000174	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CYP1B1—ovarian cancer	4.2e-05	0.000174	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	4.18e-05	0.000173	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—SLC5A5—ovarian cancer	4.17e-05	0.000173	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.16e-05	0.000172	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PPP2R1A—ovarian cancer	4.15e-05	0.000172	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—SLC5A5—ovarian cancer	4.14e-05	0.000171	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.13e-05	0.000171	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—VEGFA—ovarian cancer	4.1e-05	0.00017	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PIK3CG—ovarian cancer	4.09e-05	0.000169	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PTEN—ovarian cancer	4.09e-05	0.000169	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—NRAS—ovarian cancer	4.05e-05	0.000167	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—SLC2A1—ovarian cancer	4.03e-05	0.000167	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—SLC2A1—ovarian cancer	4e-05	0.000165	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.91e-05	0.000162	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—MAPK3—ovarian cancer	3.88e-05	0.00016	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—ABCB1—ovarian cancer	3.88e-05	0.00016	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP1B1—ovarian cancer	3.87e-05	0.00016	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—ABCB1—ovarian cancer	3.86e-05	0.000159	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.84e-05	0.000159	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYP1B1—ovarian cancer	3.83e-05	0.000158	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—TYMS—ovarian cancer	3.81e-05	0.000157	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PIK3CD—ovarian cancer	3.8e-05	0.000157	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—TYMS—ovarian cancer	3.79e-05	0.000157	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	3.73e-05	0.000154	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PIK3CB—ovarian cancer	3.73e-05	0.000154	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.71e-05	0.000153	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—MAPK1—ovarian cancer	3.69e-05	0.000153	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PIK3CD—ovarian cancer	3.6e-05	0.000149	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—FASN—ovarian cancer	3.6e-05	0.000149	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—SLC5A5—ovarian cancer	3.54e-05	0.000146	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—KRAS—ovarian cancer	3.49e-05	0.000144	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—ABCB1—ovarian cancer	3.46e-05	0.000143	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	3.43e-05	0.000142	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—SLC2A1—ovarian cancer	3.42e-05	0.000141	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—TYMS—ovarian cancer	3.4e-05	0.000141	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	3.4e-05	0.000141	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.38e-05	0.00014	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.34e-05	0.000138	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PIK3CB—ovarian cancer	3.32e-05	0.000137	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP1B1—ovarian cancer	3.27e-05	0.000135	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PTEN—ovarian cancer	3.22e-05	0.000133	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—PIK3CA—ovarian cancer	3.2e-05	0.000132	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—ABCB1—ovarian cancer	3.18e-05	0.000132	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—ABCB1—ovarian cancer	3.16e-05	0.00013	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PIK3CB—ovarian cancer	3.14e-05	0.00013	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—TYMS—ovarian cancer	3.13e-05	0.000129	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—TYMS—ovarian cancer	3.1e-05	0.000128	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—TP53—ovarian cancer	3.1e-05	0.000128	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CAV1—ovarian cancer	3.07e-05	0.000127	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CAV1—ovarian cancer	3.05e-05	0.000126	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—AKT1—ovarian cancer	3.03e-05	0.000125	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—HRAS—ovarian cancer	2.96e-05	0.000122	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.93e-05	0.000121	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.91e-05	0.000121	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	2.9e-05	0.00012	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.89e-05	0.00012	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PIK3CA—ovarian cancer	2.89e-05	0.000119	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PTEN—ovarian cancer	2.87e-05	0.000118	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PIK3CG—ovarian cancer	2.8e-05	0.000116	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PIK3CG—ovarian cancer	2.78e-05	0.000115	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CAV1—ovarian cancer	2.74e-05	0.000113	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PTEN—ovarian cancer	2.71e-05	0.000112	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—ABCB1—ovarian cancer	2.7e-05	0.000112	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—TYMS—ovarian cancer	2.65e-05	0.00011	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.62e-05	0.000108	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—AKT1—ovarian cancer	2.62e-05	0.000108	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CAV1—ovarian cancer	2.52e-05	0.000104	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CAV1—ovarian cancer	2.5e-05	0.000103	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PIK3CG—ovarian cancer	2.49e-05	0.000103	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PIK3CD—ovarian cancer	2.46e-05	0.000102	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PIK3CD—ovarian cancer	2.44e-05	0.000101	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.39e-05	9.87e-05	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—AKT1—ovarian cancer	2.36e-05	9.75e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.29e-05	9.49e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PIK3CG—ovarian cancer	2.27e-05	9.41e-05	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PIK3CA—ovarian cancer	2.27e-05	9.39e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PIK3CD—ovarian cancer	2.19e-05	9.07e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PIK3CB—ovarian cancer	2.14e-05	8.86e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CAV1—ovarian cancer	2.13e-05	8.82e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PIK3CB—ovarian cancer	2.13e-05	8.81e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.04e-05	8.43e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PIK3CA—ovarian cancer	2.02e-05	8.36e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.02e-05	8.34e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PIK3CD—ovarian cancer	2e-05	8.27e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.94e-05	8.04e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.91e-05	7.9e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PIK3CA—ovarian cancer	1.91e-05	7.9e-05	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—AKT1—ovarian cancer	1.86e-05	7.67e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PTEN—ovarian cancer	1.85e-05	7.65e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PTEN—ovarian cancer	1.84e-05	7.61e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.76e-05	7.27e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.74e-05	7.21e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.71e-05	7.07e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PTEN—ovarian cancer	1.65e-05	6.83e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—AKT1—ovarian cancer	1.65e-05	6.83e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—AKT1—ovarian cancer	1.56e-05	6.46e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PTEN—ovarian cancer	1.52e-05	6.28e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PTEN—ovarian cancer	1.51e-05	6.23e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.49e-05	6.16e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.31e-05	5.4e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PIK3CA—ovarian cancer	1.3e-05	5.37e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PTEN—ovarian cancer	1.29e-05	5.32e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.17e-05	4.82e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.07e-05	4.43e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—AKT1—ovarian cancer	1.07e-05	4.41e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.06e-05	4.39e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—AKT1—ovarian cancer	1.06e-05	4.38e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—AKT1—ovarian cancer	9.52e-06	3.94e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PIK3CA—ovarian cancer	9.08e-06	3.75e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—AKT1—ovarian cancer	8.76e-06	3.62e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—AKT1—ovarian cancer	8.68e-06	3.59e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—AKT1—ovarian cancer	7.42e-06	3.07e-05	CbGpPWpGaD
